Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
2007-03-27
2007-03-27
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C435S005000, C435S006120, C435S007720, C435S040520
Reexamination Certificate
active
10639150
ABSTRACT:
The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
REFERENCES:
patent: 6326137 (2001-12-01), Hong et al.
Bartenschlager R & Lohmann V. “Novel cell culture system for the hepatitis C virus” Antiviral Research vol. 52(2001), pp. 1-17.
Nakayama GR et al “Assessment of alamar blue assay for cellular growth and viability in vitro” J. Immunological Methods vol. 204(1997), pp. 205-208.
Taliani M. et al. “A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates” Anal. Biochem. vol. 240 (1996), pp. 60-67.
Bartenschlager, R. et al., “Novel cell culture systems for the hepatitis C virus”, Antiviral Research, vol. 52, pp. 1-17 (2001).
Blight, K.J. et al., “Efficient Initiation of HCV RNA Replication in Cell Culture”, Science, vol. 290, pp. 1972-1974 (2000).
Collier, J. et al., “Combination Therapy with Interferon-α and Ribavirin for Hepatitis C”, BioDrugs, vol. 15, No. 4, pp. 225-238 (2001).
Dymock, B.W., “Emerging therapies for hepatitis C virus infection”, Emerging Drugs, vol. 6, No. 1, pp. 13-42 (2001).
Ito, T. et al., “Acquisition of Susceptibility to Hepatitis C Virus Replication HepG2 Cells by Fusion With Primary Human Hepatocytes: Establishment of a Quantitative Assay for Hepatitis C Virus Infectivity in a Cell Culture System”, Hepatology, vol. 34, pp. 566-572 (2001).
Lauer, G.M. et al., “Hepatitis C Virus Infection”, N. Engl. J. Med., vol. 345, No. 1, pp. 41-52 (2001).
Lohmann, V. et al., “Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line”, Science, vol. 285, pp. 110-113 (1999).
Pietschmann, T. et al., “Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs”, Journal of Virology, vol. 75, No. 3, pp. 1252-1264 (2001).
Rodriguez-López, M. et al., “Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA”, Journal of General Virology, vol. 80, pp. 727-738 (1999).
Taliani, M. et al., “A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates”, Analytical Biochemistry, vol. 240, pp. 60-67 (1996).
Zhang, J.-H. et al., “A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays”, Journal of Biomolecular Screening, vol. 4, No. 2, pp. 67-73 (1999).
Bark, S.J. et al., “Fluorescent Indicators of Peptide Cleavage in the Trafficking Compartments of Living Cells: Peptides Site-Specifically Labeled with Two-Dyes”, Methods, vol. 20, No. 4, pp. 429-435 (2000).
Cho, Y.-G. et al., “In vivo assay for hepatitis C viral serine protease activity using a secreted protein”, Journal of Virological Methods, vol. 72, No. 1, pp. 109-115 (1998).
Lee, J.K. et al., “In vitrocytotoxicity tests on cultured human skin fibroblasts to predict skin irritation potential of surfactants”, Toxicology in Vitro, vol. 14, No. 4, pp. 345-349 (2000).
Gao Min
Lemm Julie A.
Nower Peter
O'Boyle Donald R.
Rigat Karen
Bristol--Myers Squibb Company
Campell Bruce R.
Frank Eve L.
Lange Keith R.
Peng Bo
LandOfFree
Hepatitis C virus assays does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus assays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus assays will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783185